Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the deletion of atazanavir 150 mg from the EML and EMLc.
The committee noted that the proposed deletion was in alignment with recommendations in the 2016 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1) and with the IATT Paediatric ARV Formulary (2), revised in 2016. The committee also noted that atazanavir 100 mg remains available on the EML and EMLc and atazanavir 300 mg remains available on the EML. Furthermore, a fixed dose combination formulation of atazanavir + ritonavir (300 mg + 100 mg) has been added to the EML in 2017.
1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:recommendations for a public health approach, second edition. Geneva: World Health Organization;
2. Policy Brief: IATT Paediatric ARV Formulary and Limited-Use List: 2016 update. Interagency Task Team
(IATT) for Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children;